Development of a transgenic mouse neurovirulence test for oral poliovirus vaccine: International collaborative study 1993-1999

Vaccine

Volumn 19, Issue 2-3, 2000, Pages 163-166

  Levenbook, Inessa ^a   Dragunsky, Eugenia ^b   Pervikov, Yuri ^c  

^a 3228 Prestwick Lane ^*  (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

International collaborative study; OPV; Tg mouse test

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; DRUG SAFETY; MOUSE; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRUS INFECTION; VIRUS VIRULENCE;

EID: 0034666746     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00190-0     Document Type: Article

References (14)

1. Requirements for poliomyelitis vaccine (oral). WHO Tech Rep Ser 1990;800:46-9.
2. Contreras G., Furesz J., Karpinski K., Grinwich K., Gardell C. Experience in Canada with the new revised monkey neurovirulence test for oral poliovirus vaccine. J. Biol. Stand. 16:1988;195-205.
3. Furesz J, Contreras G. Some aspects of the monkey neurovirulence test used for assessment of live poliovirus vaccines. In: Brown F, Lewis BP, editors. Poliovirus attenuation: Molecular mechanisms and practical aspects. Dev Biol Stand Basel, Karger 1993;78:61-70.
4. Ren R., Costantini F., Gorgacz E.J., Lee J.J., Racaniello V.R. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell. 63:1990;353-362.
5. Koike S., Taya S., Kurata T., Abe S., Ise I., Yonekawa H., Nomoto A. Transgenic mice susceptible to poliovirus. Proc. Natl. Acad. Sci. USA. 88:1991;951-955.
6. Evans D.M.A., Dunn G., Minor P.D., Schild G.C., Cann A.J., Stanway G., Almond J.W., Currey K., Maizel J.V. Jr. Increased neurovirulence associated with a single nucleotide change in a non-coding region of the Sabin type-3 poliovirus genome. Nature. 314:1985;548-550.
7. Dragunsky E., Gardner D., Taffs R., Levenbook I. Transgenic PVR Tg-1 mice for testing of poliovirus type-3 neurovirulence: comparison with monkey test. Biologicals. 21:1993;233-237.
8. Criteria for the Acceptance of Vaccines after Neurovirulence Testing. Requirements for Poliomyelitis Vaccine (Oral). Appendix 3. WHO Tech Rep Ser 1990, No. 800.
9. Dragunsky E., Chernokhvostova Y., Taffs R., Chumakov K., Gardner D., Asher D., Nomura T., Hioki K., Levenbook I. TgPVR21 mice for testing type-3 oral poliovirus vaccines: role of clinical observation and histological examination. Vaccine. 15:1997;1863-1866.
10. Hioki K. Kato H., Endo S., Saito M., Nomura T. Planned production of poliovirus-sensitive transgenic mice. Exp. Anim. 42:1993;300-303. [in Japanese].
11. Nomura T. Practical development of genetically engineered animals as human disease models. Lab. Animal Science. 47:1997;113-117.
12. Maintenance and distribution of transgenic mice susceptible to human viruses: Memorandum from a WHO Meeting. WHO Bull. OMS 1993;71:497-502.
13. Abe S., Ota Y., Koike S., Kurata T., Horie H., Nomura T., Hashizume S., Nomoto A. Neurovirulence test for oral live poliovaccines using poliovirus-sensitive transgenic mice. Virology. 206:1995;1075-1083.
14. Dragunsky E., Taffs R., Chernokhvostova E., Nomura T., Hioki K., Gardner D., Norwood L., Levenbook I. A poliovirus-susceptible transgenic mouse as a possible replacement for the monkey neurovirulence test of oral poliovirus vaccine. Biologicals. 24:1996;77-86.